These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Investigational drugs for hepatitis C. Flisiak R; Parfieniuk A Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555 [TBL] [Abstract][Full Text] [Related]
24. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment. Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL; Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795 [TBL] [Abstract][Full Text] [Related]
25. HCV treatment--no more room for interferonologists? Drenth JP N Engl J Med; 2013 May; 368(20):1931-2. PubMed ID: 23607592 [No Abstract] [Full Text] [Related]
26. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. Nelson DR Liver Int; 2011 Jan; 31 Suppl 1():53-7. PubMed ID: 21205138 [TBL] [Abstract][Full Text] [Related]
27. An overview of emerging therapies for the treatment of chronic hepatitis C. Ilyas JA; Vierling JM Clin Liver Dis; 2011 Aug; 15(3):515-36. PubMed ID: 21867934 [TBL] [Abstract][Full Text] [Related]
28. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. Yuan HJ; Jain M; Snow KK; Gale M; Lee WM; J Viral Hepat; 2010 Mar; 17(3):208-16. PubMed ID: 19656286 [TBL] [Abstract][Full Text] [Related]
29. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1. Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750 [TBL] [Abstract][Full Text] [Related]
30. Cyclophilin inhibitors for the treatment of HCV infection. Fischer G; Gallay P; Hopkins S Curr Opin Investig Drugs; 2010 Aug; 11(8):911-8. PubMed ID: 20721833 [TBL] [Abstract][Full Text] [Related]
31. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487 [TBL] [Abstract][Full Text] [Related]
32. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients. Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545 [TBL] [Abstract][Full Text] [Related]
33. Review article: HCV genotype 3 – the new treatment challenge. Ampuero J; Romero-Gómez M; Reddy KR Aliment Pharmacol Ther; 2014 Apr; 39(7):686-98. PubMed ID: 24612116 [TBL] [Abstract][Full Text] [Related]
34. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure. Yu ML; Dai CY; Huang JF; Chuang WL Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469 [No Abstract] [Full Text] [Related]
35. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy. Nakamoto S; Imazeki F; Arai M; Yasui S; Nakamura M; Haga Y; Sasaki R; Kanda T; Shirasawa H; Yokosuka O Int J Mol Sci; 2015 Sep; 16(9):21177-90. PubMed ID: 26370958 [TBL] [Abstract][Full Text] [Related]
36. New HCV therapies on the horizon. Vermehren J; Sarrazin C Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349 [TBL] [Abstract][Full Text] [Related]
37. Interferon stimulated genes and hepatitis C virus infection. Asselah T J Interferon Cytokine Res; 2012 Dec; 32(12):557-62. PubMed ID: 23151203 [TBL] [Abstract][Full Text] [Related]
38. Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure. Kalal C; Shukla A; Mohanka R; Vora M; Patel P; Shah S Hepatology; 2018 May; 67(5):2049-2050. PubMed ID: 29152769 [No Abstract] [Full Text] [Related]